2013
Breast cancer evaluation and targeted investigational therapy (BEAT-IT): A pilot prospective tissue testing to guide clinical trial selection.
Pusztai L, Mattair D, Ueno N, Valero V, Moulder S, Murray J, Alvarez R, Chavez-Mac Gregor M, Santiago L, Avritscher R, Sahin A, Hortobagyi G, Symmans W, Meric-Bernstam F, Burton E, Gonzalez-Angulo A. Breast cancer evaluation and targeted investigational therapy (BEAT-IT): A pilot prospective tissue testing to guide clinical trial selection. Journal Of Clinical Oncology 2013, 31: 532-532. DOI: 10.1200/jco.2013.31.15_suppl.532.Peer-Reviewed Original ResearchFine-needle aspirationCore needle biopsyClinical trial selectionClinical trialsTrial selectionMolecular abnormalitiesTherapeutic clinical trialsSpecific molecular abnormalitiesBreast cancer biopsiesBreast cancer evaluationElectronic medical recordsMutation analysisMechanism of actionCare therapyInvestigational therapiesOrgan dysfunctionPathological confirmationER visitsLymph nodesInvestigational agentsMetastatic sitesMedical recordsEML4-ALKNeedle biopsyNeedle aspiration
2007
Markers predicting clinical benefit in breast cancer from microtubule-targeting agents
Pusztai L. Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. Annals Of Oncology 2007, 18: xii15-xii20. PMID: 18083698, DOI: 10.1093/annonc/mdm534.Peer-Reviewed Original ResearchConceptsMicrotubule-targeting agentsSubset of patientsEstrogen receptor negativityBreast cancer patientsNon-cross resistanceMicrotubule-associated protein tauMechanism of actionReceptor negativityClinical benefitPatient groupCancer patientsClinical trialsPoor responseHER2 amplificationClinical dataClinical studiesBreast cancerTaxane resistanceBetaIII-tubulinProtein tauP-glycoproteinPharmacogenomic analysisTaxanesLow expressionPatients